North America Influenza Vaccines Market

The North America influenza vaccines market is expected to grow from US$ 3,155.29 million in 2022 to US$ 4,909.00 million by 2028; it is estimated to grow at a CAGR of 7.6% from 2022 to 2028.

Increase in Government Support to Promote Influenza Vaccination Boosts North America Influenza Vaccines Market

Several governments of North American countries are supporting the promotion of vaccination through multiple activities and programs. By 2022, enough vaccines have been secured to cover all risk groups eligible for a government-funded flu vaccine through the National Immunisation Program (NIP). A few more instances of government support for influenza vaccination include: In July 2022, Public Services and Procurement Minister Filomena Tassi and Health Minister Jean-Yves Duclos announced that the Government of Canada had signed a new contract with GlaxoSmithKline (GSK) to support a sustainable influenza pandemic readiness. The Government of Canada maintains pandemic influenza vaccine preparedness in the event of an influenza pandemic. It has had a contract with GSK to provide seasonal and pandemic influenza vaccines since 2001. Pandemic influenzas are unpredictable but occur when a new strain of influenza virus emerges, spreads widely, and causes the disease. In July 2022, Seniors and Long-term Care Minister Scott Johnston and Health Minister Audrey Gordon announced that the Manitoba government would expand the high-dose flu vaccine eligibility to include all adults aged 65 and over to ensure that more of the Manitoba population is protected against influenza. The Victorian government proposed a grant and reimbursement program to help GPs and pharmacies improve access and uptake of the influenza vaccines by June and July 2022. In September 2019, the former US President Donald Trump signed an executive order to promote the development of better vaccines against seasonal flu and the potential for pandemic flu outbreaks. In October 2021, the Provincial Government encouraged all Newfoundlanders and Labradorians to get a flu shot. From October 25, 2021, the Regional Health Authorities (RHAs) have begun hosting free flu vaccination clinics. Thus, increasing government support to promote the influenza vaccination is driving the North America influenza vaccines market.

North America Influenza Vaccines Market Overview

The North America influenza vaccines market is segmented into the US, Canada, and Mexico. The US held the largest share of the market in 2022. The rising number of flu cases, growing research & development activities on flu vaccines, and increasing demand for advanced vaccines to prevent diseases are among the prominent factors propelling the market growth in this region. 

North America Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Million)

North America Influenza Vaccines Strategic Insights

Strategic insights for the North America Influenza Vaccines provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

North America Influenza Vaccines Report Scope

North America Influenza Vaccines Regional Insights

The geographic scope of the North America Influenza Vaccines refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

North America Influenza Vaccines Market Segmentation

The North America influenza vaccines market is segmented on the basis of vaccine type, virus type, technology, route of administration, target group, and country.

Based on vaccine type, the North America influenza vaccines market is bifurcated into quadrivalent vaccines and trivalent vaccines. The quadrivalent vaccines segment registered a larger share of the market in 2022.

Based on virus type, the North America influenza vaccines market is bifurcated into influenza virus type A and influenza virus type B. The influenza virus type A segment held a larger share of the market in 2022.

Based on technology, the North America influenza vaccines market is divided into egg-based and cell-based. The egg-based segment held a larger share of the market in 2022.

Based on route of administration, the North America influenza vaccines market is divided into injection and nasal spray. The injection segment held a larger share of the market in 2022.

Based on target group, the North America influenza vaccines market is segmented into infants, children, adults, and elderly people. The infants segment held the largest share of the market in 2022.

Based on country, the North America influenza vaccines market is segmented into the US, Mexico, and Canada. The US dominated the market in 2022.

AstraZeneca; Emergent BioSolutions Inc.; GlaxoSmithKline plc.; Mitsubishi Chemical Group Corporation; Moderna, Inc.; MYLAN N.V.; Sanofi; SEQIRUS; and Serum Institute of India Pvt. Ltd are the leading companies operating in the North America influenza vaccines market.